Praxis Precision Medicines
Clinical trials sponsored by Praxis Precision Medicines, explained in plain language.
-
Promising new drug targets severe seizures in babies with rare genetic disorder
Disease control Recruiting nowThis study tests a medicine called elsunersen in 50 children with a rare genetic epilepsy caused by changes in the SCN2A gene. The goal is to see if it can safely reduce the number of seizures. Children must have had seizures before 3 months old and have at least 4 seizures per m…
Phase: PHASE3 • Sponsor: Praxis Precision Medicines • Aim: Disease control
Last updated May 17, 2026 16:07 UTC
-
New seizure drug shows promise in major trial
Disease control Recruiting nowThis study tests a new medicine called vormatrigine for adults with focal seizures (a type of epilepsy). About 300 people who already take 1 to 3 seizure drugs will receive either vormatrigine or a placebo. The goal is to see if vormatrigine reduces seizure frequency more than pl…
Phase: PHASE3 • Sponsor: Praxis Precision Medicines • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for kids with hard-to-treat epilepsy: drug trial targets seizure frequency
Disease control Recruiting nowThis study tests an experimental drug called relutrigine in 160 children with a severe form of epilepsy called developmental and epileptic encephalopathy (DEE). The goal is to see if the drug can safely reduce monthly seizures compared to a placebo. After the main study, all part…
Phase: PHASE3 • Sponsor: Praxis Precision Medicines • Aim: Disease control
Last updated May 13, 2026 16:03 UTC